Registry of Lobbyists
Subject matters | Details | Categories |
---|---|---|
Federal-Provincial Relations,
Foreign Affairs,
Health,
Industry,
Intellectual Property,
International Trade,
Research and Development,
Science and Technology,
Small Business,
Taxation and Finance
|
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
|
Legislative Proposal, Bill or Resolution
|
Foreign Affairs,
Health,
Infrastructure,
International Trade,
Research and Development,
Science and Technology,
Small Business,
Taxation and Finance
|
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
|
Policies or Program
|
Foreign Affairs,
Health,
Intellectual Property,
International Trade,
Research and Development,
Science and Technology
|
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
|
Policies or Program
|
Foreign Affairs,
Health,
Intellectual Property,
International Trade,
Research and Development,
Science and Technology
|
Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products
|
Policies or Program
|
Environment,
Health,
Intellectual Property,
Research and Development,
Science and Technology
|
Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Health,
Research and Development,
Science and Technology,
Taxation and Finance
|
Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
|
Policies or Program
|
Health,
Intellectual Property,
Research and Development,
Science and Technology
|
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
|
Policies or Program
|
Consumer Issues,
Federal-Provincial Relations,
Health,
Intellectual Property,
Research and Development,
Science and Technology,
Taxation and Finance
|
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
|
Policies or Program
|
Health,
Intellectual Property,
International Trade,
Research and Development,
Science and Technology
|
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
|
Regulation
|
Agriculture,
Consumer Issues,
Foreign Affairs,
Health,
International Relations,
International Trade,
Taxation and Finance
|
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Foreign Affairs,
Health,
Intellectual Property,
International Relations,
International Trade,
Research and Development,
Science and Technology,
Taxation and Finance
|
Free trade agreements as they relate to the biopharmaceutical industry
|
Policies or Program
|
Agriculture,
Consumer Issues,
Health,
Intellectual Property,
Research and Development,
Science and Technology,
Taxation and Finance
|
Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
|
Regulation
|
Health,
Intellectual Property,
International Trade,
Research and Development,
Science and Technology,
Taxation and Finance
|
Income Tax Act as it relates to biopharmaceutical products
|
Legislative Proposal, Bill or Resolution
|
Health,
Industry,
Intellectual Property,
Research and Development,
Science and Technology,
Small Business,
Taxation and Finance
|
National Strategy for Drugs for Rare Diseases
|
Policies or Program,
Regulation
|
Health,
Intellectual Property,
International Relations,
International Trade,
Research and Development,
Science and Technology,
Taxation and Finance
|
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
|
Legislative Proposal, Bill or Resolution
|
Health,
Intellectual Property,
International Relations,
International Trade,
Research and Development,
Science and Technology,
Taxation and Finance
|
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
|
Regulation
|
Health,
Intellectual Property,
International Relations,
International Trade,
Research and Development,
Science and Technology,
Taxation and Finance
|
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
|
Regulation
|
Health,
Intellectual Property,
International Relations,
International Trade,
Research and Development,
Science and Technology,
Taxation and Finance
|
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
|
Regulation
|
Constitutional Issues,
Consumer Issues,
Federal-Provincial Relations,
Health,
Research and Development,
Science and Technology
|
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
|
Policies or Program
|
Consumer Issues,
Federal-Provincial Relations,
Health,
Intellectual Property,
International Trade,
Research and Development,
Science and Technology,
Taxation and Finance
|
Proposed pharmacare legislation related to any future national pharmacare program
|
Legislative Proposal, Bill or Resolution
|
Health,
Intellectual Property,
Research and Development,
Science and Technology,
Taxation and Finance
|
Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
|
Policies or Program
|
Health,
Intellectual Property,
International Trade,
Research and Development,
Science and Technology,
Taxation and Finance
|
Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
|
Policies or Program
|
Agriculture,
Government Procurement,
Health,
Intellectual Property,
International Trade,
Research and Development,
Science and Technology,
Taxation and Finance
|
World Health Organization (WHO) issues concerning the biopharmaceutical industry
|
Policies or Program
|
Health,
Intellectual Property,
International Trade,
Research and Development,
Science and Technology,
Taxation and Finance
|
World Intellectual Property Organization (WIPO) issues concerning the biopharmaceutical industry
|
Policies or Program
|
Health,
Intellectual Property,
International Trade,
Research and Development,
Science and Technology,
Taxation and Finance
|
World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"
|
Policies or Program
|
Subject matters | Details | Categories |
---|---|---|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Free trade treaty agreement as they relate to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to India, the European Union, Japan, MERCOSUR and the Trans-Pacific Partnership
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Health Canada’s Interim Orders relating to COVID-19: The Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19; The Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19; The Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19; The Interim Order Respecting the Prevention and Alleviation of Shortages of Drugs in Relation to Covid-19
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Income Tax Act as it relates to biopharmaceutical products
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
New Substances Notification Regulations as it relates to the biopharmaceutical industry
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB)
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Proposed pharmacare legislation related to any future national pharmacare program
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Smart Regulations as it relates to the biopharmaceutical industry
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
The government's Science and Technology strategy as it relates to the biopharmaceutical industry
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
World Health Organization (WHO) issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG)
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
World Intellectual Property Organization (WIPO) issues concerning the protection of and access to intellectual property
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"
|
Policies or Program
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Date | DPOH, Position Title | Government Institution | Subject Matters |
---|---|---|
2024-07-24 |
|
Consumer Issues, Federal-Provincial Relations, Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance |
2024-07-18 |
|
Consumer Issues, Federal-Provincial Relations, Foreign Affairs, Health, Industry, Infrastructure, Intellectual Property, International Trade, Research and Development, Science and Technology, Small Business, Taxation and Finance |
2024-06-27 |
|
Consumer Issues, Federal-Provincial Relations, Health, Industry, Intellectual Property, International Trade, Research and Development, Science and Technology, Small Business, Taxation and Finance |
2024-06-19 |
|
Consumer Issues, Federal-Provincial Relations, Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance |
2024-06-13 |
|
Consumer Issues, Federal-Provincial Relations, Foreign Affairs, Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance |
2024-06-12 |
|
Consumer Issues, Federal-Provincial Relations, Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance |
2024-06-10 |
|
Consumer Issues, Federal-Provincial Relations, Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance |
2024-06-07 |
|
Agriculture, Consumer Issues, Foreign Affairs, Health, International Relations, International Trade, Taxation and Finance, Intellectual Property, Research and Development, Science and Technology |
2024-05-28 |
|
Consumer Issues, Federal-Provincial Relations, Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance |
2024-05-23 |
|
Consumer Issues, Federal-Provincial Relations, Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance |
2024-05-23 |
|
Agriculture, Consumer Issues, Federal-Provincial Relations, Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Small Business, Taxation and Finance, Industry |
2024-05-07 |
|
Consumer Issues, Federal-Provincial Relations, Foreign Affairs, Health, Industry, Intellectual Property, International Trade, Research and Development, Science and Technology, Small Business, Taxation and Finance |
2024-05-06 |
|
Consumer Issues, Federal-Provincial Relations, Health, Industry, Intellectual Property, International Trade, Research and Development, Science and Technology, Small Business, Taxation and Finance |
2024-04-15 |
|
Federal-Provincial Relations, Foreign Affairs, Health, Industry, Infrastructure, Intellectual Property, International Trade, Research and Development, Science and Technology, Small Business, Taxation and Finance |
2024-04-15 |
|
Foreign Affairs, Health, Infrastructure, International Trade, Research and Development, Science and Technology, Small Business, Taxation and Finance |
2024-04-15 |
|
Federal-Provincial Relations, Foreign Affairs, Health, Industry, Infrastructure, Intellectual Property, International Trade, Research and Development, Science and Technology, Small Business, Taxation and Finance |
2024-03-01 |
|
Health |
2024-01-18 |
|
Health, Industry |
2024-01-11 |
|
Health, Industry |
2024-01-05 |
|
Health |
2023-12-12 |
|
Health |
2023-12-12 |
|
Health |
2023-12-12 |
|
Health |
2023-12-08 |
|
Health |
2023-11-08 |
|
Health, Industry, Science and Technology |
2023-11-08 |
|
Health, Industry |
2023-11-08 |
|
Health, Industry |
2023-11-08 |
|
Health, Industry |
2023-11-07 |
|
Health, Industry, Science and Technology, Small Business |
2023-11-07 |
|
Health, Industry |
2023-11-07 |
|
Health |
2023-11-07 |
|
Health, Industry, Small Business |
2023-11-07 |
|
Health |
2023-11-07 |
|
Health, Industry |
2023-11-07 |
|
Health |
2023-11-07 |
|
Health, Regional Development, Science and Technology |
2023-11-07 |
|
Health, Industry |
2023-11-07 |
|
Health, Industry, Science and Technology |
2023-11-07 |
|
Health, Industry |
2023-11-07 |
|
Health, Industry, Science and Technology |
2023-11-06 |
|
Health |
2023-11-06 |
|
Health, Industry, Science and Technology |
2023-11-06 |
|
Health, Industry |
2023-11-06 |
|
Health |
2023-11-06 |
|
Health, Industry |
2023-11-06 |
|
Health, Industry |
2023-11-06 |
|
Health, Industry, Science and Technology |
2023-11-06 |
|
Health |
2023-11-06 |
|
Health, Industry |
2023-11-06 |
|
Health, Industry, Science and Technology |
2023-11-06 |
|
Health |
2023-11-06 |
|
Health, Industry |
2023-11-01 |
|
Health |
2023-10-05 |
|
Health, Industry |
2023-10-04 |
|
Health, Industry |
2023-09-21 |
|
Health |
2023-09-14 |
|
Health, Industry |